The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Evaluating erythroid precursors in patients with LR-MDS to predict response to ESAs
In this video, Valeria Santini, MD, University of Florence, Florence, Italy, shares some insights into a study which used flow cytometry to evaluate variations in erythroid precursors and identify which patients with lower-risk myelodysplastic syndromes (LR-MDS) are likely to respond to treatment with erythropoiesis-stimulating agents (ESAs). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis, AbbVie, BMS, Gilead, Menarini, Geron, Otsuka: Honoraria.
